CITIUS ONCOLOGY, INC.

Citius Oncology, Inc. (Nasdaq: TENK) is the post-combination company formed through the de-SPAC transaction between TenX Keane Acquisition Corp and Citius Oncology, a biopharmaceutical spin-off from Citius Pharmaceuticals focused on oncology therapeutics. TenX Keane Acquisition Corp, sponsored by TenX Keane Capital LLC, completed its IPO in 2021 and targeted the healthcare and life sciences sector. The combined entity operates in the oncology biopharmaceutical space, with its lead asset being LYMPHIR, an FDA-approved therapy for relapsed or refractory cutaneous T-cell lymphoma. The company filed this 8-K with the SEC on October 27, 2025. Sign up at SpacDesk for full filing history, sponsor profiles, and transaction data on TENK and hundreds of other SPACs.